TR201903978T4 - L-ornitin fenil asetat yapım yöntemleri. - Google Patents

L-ornitin fenil asetat yapım yöntemleri. Download PDF

Info

Publication number
TR201903978T4
TR201903978T4 TR2019/03978T TR201903978T TR201903978T4 TR 201903978 T4 TR201903978 T4 TR 201903978T4 TR 2019/03978 T TR2019/03978 T TR 2019/03978T TR 201903978 T TR201903978 T TR 201903978T TR 201903978 T4 TR201903978 T4 TR 201903978T4
Authority
TR
Turkey
Prior art keywords
phenyl acetate
ornithine phenyl
making methods
ornithine
acetate making
Prior art date
Application number
TR2019/03978T
Other languages
English (en)
Inventor
H Anderson Keith
Behling Jim
Henderson Dougan Christine
William Watt Stephen
Manini Peter
Figini Attilia
Original Assignee
Ocera Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ocera Therapeutics Inc filed Critical Ocera Therapeutics Inc
Publication of TR201903978T4 publication Critical patent/TR201903978T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
    • C07C227/18—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C07C57/32—Phenylacetic acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Buluş, L-ornitin fenil asetat tuzu yapımı için bir proses olup, bir fenil asetik asit ve bir çözücü olarak bir bazın karıştırılması yoluyla fenil asetat tuzunun bir çözeltisinin hazırlanması, fenil asetat tuzunun bir çözeltisi ile L-ornitin benzoat'ın birbirine karıştırılması ve L-ornitin fenil asetat içeren bir bileşimin izole edilmesi işlem adımlarını içermesi ile ilgilidir.
TR2019/03978T 2010-10-06 2011-10-05 L-ornitin fenil asetat yapım yöntemleri. TR201903978T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39058510P 2010-10-06 2010-10-06

Publications (1)

Publication Number Publication Date
TR201903978T4 true TR201903978T4 (tr) 2019-04-22

Family

ID=45928120

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/03978T TR201903978T4 (tr) 2010-10-06 2011-10-05 L-ornitin fenil asetat yapım yöntemleri.

Country Status (16)

Country Link
US (2) US8946473B2 (tr)
EP (1) EP2625162B1 (tr)
JP (1) JP6087284B2 (tr)
KR (1) KR101888215B1 (tr)
CN (1) CN103502203B (tr)
AU (1) AU2011312042B2 (tr)
BR (1) BR112013008054B1 (tr)
CA (1) CA2813563C (tr)
EA (1) EA028395B1 (tr)
ES (1) ES2720148T3 (tr)
IL (1) IL225512A (tr)
MX (1) MX360062B (tr)
NZ (1) NZ609191A (tr)
SG (1) SG189231A1 (tr)
TR (1) TR201903978T4 (tr)
WO (1) WO2012048043A1 (tr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1824563E (pt) 2004-11-26 2010-05-17 Ucl Business Plc Composições compreendendo ornitina e fenilacetato ou fenilbutirato para tratamento de encefalopatia hepática
EA034409B1 (ru) 2009-04-03 2020-02-05 Осера Терапьютикс, Инк. Способы получения кристаллического фенилацетата l-орнитина
EP2799067B1 (en) 2009-06-08 2019-04-03 UCL Business PLC Treatment of brain inflammation using L-Ornithine Phenylacetate
JP6087284B2 (ja) 2010-10-06 2017-03-01 オセラ セラピューティクス， インコーポレイテッド Ｌ−オルニチンフェニルアセテートを製造するための方法
KR20230018526A (ko) 2014-11-24 2023-02-07 유씨엘 비즈니스 리미티드 암모니아-저감 치료를 이용한 간성상세포 활성화와 연관된 질병의 치료
CN113599350A (zh) * 2015-04-20 2021-11-05 欧塞拉治疗有限公司 L-鸟氨酸苯乙酸盐制剂
US10835506B2 (en) 2015-08-18 2020-11-17 Ocera Therapeutics, Inc. Treatment and prevention of muscle loss using L-ornithine in combination with at least one of phenylacetate and phenylbutyrate
US11219611B2 (en) 2015-11-13 2022-01-11 Ocera Therapeutics, Inc. Formulations of L-ornithine phenylacetate
EP3373923A4 (en) * 2015-11-13 2019-07-03 Ocera Therapeutics, Inc. FORMULATION OF L-ORNITHIN PHENYL ACETATE
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
IL270413B (en) * 2017-05-11 2022-08-01 Ocera Therapeutics Inc Processes of making l-ornithine phenylacetate
AU2018318112A1 (en) 2017-08-14 2020-02-13 Axcella Health Inc. Amino acid for the treatment of liver disease
US10596136B2 (en) 2018-06-20 2020-03-24 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle
WO2024261477A1 (en) 2023-06-20 2024-12-26 Yaqrit Limited Combination of tlr4 antagonist, ornithine and phenylacetate or phenylbutyrate

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB965637A (en) 1962-04-23 1964-08-06 Tanabe Seiyaku Co L-ornithine l-aspartate
NL302572A (tr) 1962-12-27
GB1067742A (en) 1963-09-16 1967-05-03 Kyowa Hakko Kogyo Kk Process for the preparation of l-ornithine l-aspartate
ZA716628B (en) 1970-10-15 1972-06-28 Richardson Merrell Spa Composition and method for treatment of hepatic disease and mental fatigue
US4100293A (en) 1974-04-15 1978-07-11 The Johns Hopkins University Treatment of hepatic disorders with therapeutic compositions comprising keto analogs of essential amino acids
US3950529A (en) 1975-02-03 1976-04-13 Massachusetts General Hospital Amino acid formulations for patients with liver disease and method of using same
US4320146A (en) 1978-03-17 1982-03-16 The Johns Hopkins University Treatment of hepatic and renal disorders with ornithine and arginine salts of branched chain keto acids
US4228099A (en) 1978-03-17 1980-10-14 The Johns Hopkins University Ornithine and arginine salts of branched chain keto acids and uses in treatment of hepatic and renal disorders
US4352814A (en) 1979-04-18 1982-10-05 The Johns Hopkins University Treatment of hepatic and renal disorders with mixed salts of essential or semi-essential amino acids and nitrogen-free analogs
US4284647A (en) 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
US4457942A (en) 1982-08-20 1984-07-03 Brusilow Saul W Process for waste nitrogen removal
US5591613A (en) 1990-07-02 1997-01-07 Degussa Aktiengesellschaft Method for the preparation of D-arginine and L-ornithine
DE4020980C1 (tr) 1990-07-02 1991-09-26 Degussa Ag, 6000 Frankfurt, De
JP3127484B2 (ja) 1991-02-28 2001-01-22 味の素株式会社 肝炎治療薬
US5767086A (en) 1992-04-03 1998-06-16 Terrapin Technologies, Inc. Bone marrow stimulation by certain glutathione analogs
ATE153299T1 (de) 1992-09-09 1997-06-15 Fisons Plc Pharmazeutisches verpacken
US5571783A (en) 1993-03-09 1996-11-05 Clintec Nutrition Company Composition and method for treating patients with hepatic disease
JP3273578B2 (ja) * 1993-09-21 2002-04-08 第一化学薬品株式会社 オルニチンと酸性アミノ酸類又はケト酸類との塩の製造法
US5856481A (en) 1994-07-28 1999-01-05 Syntex (U.S.A.) Inc. 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
WO1997030167A1 (en) 1996-02-13 1997-08-21 The Trustees Of The University Of Pennsylvania Method of treating liver disorders
ZA986614B (en) 1997-07-25 1999-01-27 Gilead Sciences Nucleotide analog composition
GB9815567D0 (en) 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
US6258849B1 (en) 1998-07-23 2001-07-10 Stanislaw R. Burzynski Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate
AU4778700A (en) 1999-05-21 2000-12-12 Takeda Chemical Industries Ltd. Liver function controlling agents
US6768024B1 (en) 2000-08-04 2004-07-27 Lion Bioscience Ag Triamine derivative melanocortin receptor ligands and methods of using same
JP3211824B1 (ja) 2000-10-26 2001-09-25 味の素株式会社 分岐鎖アミノ酸含有医薬用顆粒製剤とその製造方法
DE60233558D1 (de) 2001-03-15 2009-10-15 Takashi Abe Aminosäurezusammensetzungen zur linderung einer fehlfunktion der leber
US6503530B1 (en) 2001-11-01 2003-01-07 Chunghee Kimberly Kang Method of preventing development of severe metabolic derangement in inborn errors of metabolism
US20030105104A1 (en) 2001-11-27 2003-06-05 Burzynski Stanislaw R. Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy
US20030195255A1 (en) 2002-04-12 2003-10-16 Summar Marshall L. Method for treating hepatic encephalopathies
US20040229948A1 (en) 2002-04-12 2004-11-18 Summar Marshall L. Method for preventing hepatic encephalopathic episodes
CN1383815A (zh) 2002-05-08 2002-12-11 刘万忠 防治肝病、肝性脑病的鸟氨酸和门冬氨酸的复方制剂及其制备方法
US20040152784A1 (en) 2002-07-23 2004-08-05 Special Products Limited Pharmaceutical composition and method for treatment of a urea cycle deficiency or sickle-cell anaemia
AU2003261825A1 (en) 2002-08-30 2004-03-19 Ajinomoto Co., Inc. Therapeutic agent for hepatic disease
US20050059150A1 (en) 2003-09-17 2005-03-17 Becton, Dickinson And Company Environments that maintain function of primary liver cells
MXPA03009902A (es) * 2003-10-29 2005-05-03 Manuel Francisco Lara Och Jose Compuestos para reducir la hiperamonemia en pacientes con cirrosis u otras incapacidad para la eliminacion de amonio.
CA2556752C (en) 2004-02-23 2016-02-02 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
WO2005108339A2 (en) 2004-05-06 2005-11-17 Osteologix A/S High yield and rapid syntheses methods for producing metallo-organic salts
JP2008511611A (ja) 2004-08-30 2008-04-17 ルナメツド・インコーポレーテツド 治療用４−フェニル酪酸制御放出製剤
PT1824563E (pt) 2004-11-26 2010-05-17 Ucl Business Plc Composições compreendendo ornitina e fenilacetato ou fenilbutirato para tratamento de encefalopatia hepática
HRP20140476T1 (hr) 2005-11-17 2014-07-18 Silverstone Pharma Est. Stabilni oblik amorfnih soli perindoprila, postupak njihove pripreme, posebno industrijske pripreme i njihova uporaba u lijeäśenju hipertenzije
CN201421432Y (zh) * 2009-02-20 2010-03-10 山东师范大学 一种相干衍射成像处理装置
EA034409B1 (ru) 2009-04-03 2020-02-05 Осера Терапьютикс, Инк. Способы получения кристаллического фенилацетата l-орнитина
EP2799067B1 (en) 2009-06-08 2019-04-03 UCL Business PLC Treatment of brain inflammation using L-Ornithine Phenylacetate
JP6087284B2 (ja) 2010-10-06 2017-03-01 オセラ セラピューティクス， インコーポレイテッド Ｌ−オルニチンフェニルアセテートを製造するための方法

Also Published As

Publication number Publication date
IL225512A0 (en) 2013-06-27
AU2011312042B2 (en) 2015-08-20
AU2011312042A1 (en) 2013-05-02
ES2720148T3 (es) 2019-07-18
US20150133684A1 (en) 2015-05-14
CN103502203A (zh) 2014-01-08
CA2813563A1 (en) 2012-04-12
EP2625162A4 (en) 2014-06-25
CN103502203B (zh) 2016-09-07
KR20140053807A (ko) 2014-05-08
MX360062B (es) 2018-10-22
BR112013008054B1 (pt) 2019-04-09
JP6087284B2 (ja) 2017-03-01
WO2012048043A1 (en) 2012-04-12
SG189231A1 (en) 2013-05-31
BR112013008054A2 (pt) 2016-06-14
EA201390403A1 (ru) 2013-09-30
US9260379B2 (en) 2016-02-16
CA2813563C (en) 2019-02-26
EP2625162A1 (en) 2013-08-14
KR101888215B1 (ko) 2018-09-20
EP2625162B1 (en) 2019-03-13
US8946473B2 (en) 2015-02-03
US20130211135A1 (en) 2013-08-15
NZ609191A (en) 2015-06-26
IL225512A (en) 2017-12-31
MX2013003764A (es) 2013-05-20
EA028395B1 (ru) 2017-11-30
JP2013542935A (ja) 2013-11-28

Similar Documents

Publication Publication Date Title
TR201903978T4 (tr) L-ornitin fenil asetat yapım yöntemleri.
MY156938A (en) Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application
UA114611C2 (uk) Пестицидні композиції і способи, що їх стосуються
BR112012017831A8 (pt) micro-organismos produtores de ácido eicosapentaenoico, composições de ácido graxo e métodos de fabricação e uso dos mesmos
MA33939B1 (fr) 5-alcynyl-pyrimidines
UA111626C2 (uk) Похідні дигідрохінолін-2-ону
ECSP13012958A (es) Inhibidores de benzodioxano de la producción de leucotrieno.
BR112015015528A8 (pt) composição e método para produzir um composto
NZ704662A (en) Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
EA201391313A1 (ru) C4-монометилтритерпеноидные производные и способы их применения
NZ705213A (en) C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
EA201490474A1 (ru) Аминохиназолины в качестве ингибиторов киназ
MX350211B (es) Proceso para la preparacion del etil-ester del acido n- (4-ciclohexil-3-trifluoro-metil-benciloxi) -acetimidico.
BR112013003216A2 (pt) composições sintéticas de ácido biliar e métodos
WO2013072768A3 (en) Synthetic derivatives of mpl and uses thereof
WO2011126245A3 (en) Novel method of preparing vanadosilicate molecular sieve and novel vanadosilicate molecular sieve
UA110128C2 (uk) Індолкарбоксаміди та бензімідазолкарбоксаміди як інсектициди та акарициди
MA33948B1 (fr) Dérivés d'acide 3-hétéroaroylamino-propionique substitues par oxygène et leur utilisation en tant qu'agents pharmaceutiques.
EA201300443A1 (ru) Способ получения дигидроптеридинонов и их промежуточных продуктов
MY164880A (en) Process for the preparation of isoxazolyl-methoxy-nicotinic acids
IN2014MN00850A (tr)
MX2012007870A (es) Derivados de acido carboxilico que comprende un anillo de oxazolopirimidina 2, 5, 7-sustituido.
IN2015DN00085A (tr)
MX2013013262A (es) Derivados de ciclododecadienona como ingredientes de perfumado.
TN2014000329A1 (en) Method for preparing compound by novel michael addition reaction using water or various acids as additive